CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Phoenix, Arizona, United States and 45 other locations
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Phoenix, Arizona, United States and 67 other locations
reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...
Phase 3
Chandler, Arizona, United States of America and 75 other locations
and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...
Phase 1, Phase 2
Phoenix, Arizona, United States and 18 other locations
hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesi...
Phase 2
Phoenix, Arizona, United States
on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's...
Phase 2
Sun City, Arizona, United States and 34 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Phoenix, Arizona, United States and 109 other locations
-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.Part A consists of a Screening Period (up t...
Phase 1
Tempe, Arizona, United States and 24 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
Phoenix, Arizona, United States and 246 other locations
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease...
Phase 3
Phoenix, Arizona, United States and 218 other locations
Clinical trials
Research sites
Resources
Legal